On the morning of December 17, 2009, UPMC physicians used Gamma Knife® surgery to treat the center's 10,000th patient, an 81-year-old male with a tumor deep in his brainstem, a site where traditional surgery would have been impossible. Gamma Knife surgery is performed using Elekta's Leksell Gamma Knife system, which directs up to 201 pencil-thin beams of therapeutic radiation precisely on brain tumors and other targets in the head.
The 10,000th patient came to UPMC with worsening balance problems. A magnetic resonance imaging (MRI) scan of his brain revealed the small lesion, known as a metastasis -- a secondary tumor whose origin was a primary tumor located somewhere else in his body. The site of this patient's primary lesion was unclear, as are approximately 30 percent of cancers that go to the brain, said L. Dade Lunsford, M.D., Lars Leksell Professor and Distinguished Professor of Neurological Surgery at the University of Pittsburgh, and co-director, Center for Image-Guided Neurosurgery, UPMC.
"Because the patient had no known primary tumor, we performed a minimally invasive biopsy of the brain tumor during a procedure that began at 6:30 a.m. We confirmed that the lesion was a metastatic tumor requiring intervention," said Dr. Lunsford, who was the first clinician to use Leksell Gamma Knife in the United States. "At 9:30, we used our Leksell Gamma Knife® Perfexion(TM) system to deliver the radiosurgery, which took about 38 minutes."
The patient is in excellent condition, and went home after his biopsy followed by Gamma Knife surgery, UPMC officials reported.
UPMC treated its first case in 1987, a patient with an acoustic neuroma, a benign tumor of the nerve that connects the ear to the brain.
Since 1987, and particularly in the last 15 years, UPMC has used Leksell Gamma Knife to treat almost 4,000 patients who had one or more metastases. Although historically, clinicians have turned to Gamma Knife surgery when whole brain radiation therapy fails or if new tumors arise, this non-invasive technique is rapidly becoming the first treatment option, Dr. Lunsford noted.